目的:基于真实世界分析健脾益胃方对胃癌根治术后化疗不良反应及生存期的影响。方法:收集胃癌根治术后行SOX方案辅助化疗的患者,按是否长期接受健脾益胃方治疗分为联合治疗组和单纯化疗组,记录患者化疗不良反应发生情况,Kaplan-Meier法...目的:基于真实世界分析健脾益胃方对胃癌根治术后化疗不良反应及生存期的影响。方法:收集胃癌根治术后行SOX方案辅助化疗的患者,按是否长期接受健脾益胃方治疗分为联合治疗组和单纯化疗组,记录患者化疗不良反应发生情况,Kaplan-Meier法绘制生存曲线,Log-rank法检验两组生存情况差异。结果:共96例患者纳入研究,联合治疗组45例,单纯化疗组51例,3~4度中性粒细胞减低、血小板减低、恶心呕吐、周围神经毒性发生率单纯化疗组显著高于联合治疗组(P=0.013,P=0.008,P=0.025,P=0.045)。联合治疗组与单纯化疗组中位无病生存期分别为33.4 vs 26.1个月,中位总生存期分别为57.7 vs 48.5个月,差异有统计学意义(P=0.011,P=0.002)。结论:健脾益胃方联合SOX方案能减轻化疗不良反应,降低复发率,延长生存期。展开更多
目的评价健脾理气抑瘤方联合细胞因子介导的杀伤细胞（cytokine-induced killer,CIK）治疗晚期肝细胞癌（hepatocellular carcinoma,HCC）的临床疗效。方法自2011年1月—2014年1月共纳入60例晚期HCC患者,根据是否愿意服用健脾理气抑瘤方...目的评价健脾理气抑瘤方联合细胞因子介导的杀伤细胞（cytokine-induced killer,CIK）治疗晚期肝细胞癌（hepatocellular carcinoma,HCC）的临床疗效。方法自2011年1月—2014年1月共纳入60例晚期HCC患者,根据是否愿意服用健脾理气抑瘤方,分为治疗组和对照组,每组30例。两组均给予CIK细胞治疗：CIK细胞1~3×10~9个/次,第1~3天进行静脉滴注,每天1次;同时治疗组予健脾理气抑瘤方汤剂,对照组予辨证中药汤剂,两组均接受2周期以上的治疗。观察两组患者的疾病控制率（disease control rate,DCR）、疾病进展时间（time to progress,TTP）、总生存期（overall su rvival,OS）、体能状态评分（performance status scale,PS）、Child-Pugh评分及不良反应,并作亚组分析。结果截至2014年5月31日,两组所有患者均达到临床终点。治疗组TTP为3.5个月（95%CI 3.30~4.10）,优于对照组2.5个月（95%CI 2.32~2.68）,差异有统计学意义（P〈0.05）;治疗组和对照组DCR分别为36.7%和30.0%,OS为5.2个月（95%CI 4.53~5.87）和4.6个月（95%CI 4.06~5.14）,差异均无统计学意义（P〉0.05）。治疗组治疗后PS[（1.60±0.10）分]低于治疗前[（1.80±0.09）分],差异有统计学意义（P〈0.05）。在PS 0~1、2分和Child-Pugh评分为A级时,治疗组TTP均长于对照组（P〈0.05）。治疗期间两组患者未见明显不良反应。结论健脾理气抑瘤方联合CIK细胞较辨证中药治疗组可延长患者TTP及改善体力状态评分,且在体力状态评分0~2分或Child-Pugh评分为A级的情况下,可能是晚期HCC患者的更优治疗方案。展开更多
Background： Tat-interacting protein 30 （TIP30） has been reported to be a tumor suppressor, with reduced or absent expression in various tumors. However, its role in bladder urothelial cancer （BUC） has not been in...Background： Tat-interacting protein 30 （TIP30） has been reported to be a tumor suppressor, with reduced or absent expression in various tumors. However, its role in bladder urothelial cancer （BUC） has not been investigated. Therefore, herein, we investigated the expression of T1P30 protein in BUC and normal bladder mucosa and the clinical significance of TIP30 expression in the prognosis of BUC. Methods： We reviewed data from 79 cases of BUC and 15 adjacent tissue samples from 79 patients treated at our institution between 2004 and 2007. TIP30 expression was examined by immunohistochemistry. The relationship between TIP30 expression and tumor stage, histological grade, and survival was analyzed. Differences between groups were evaluated using the t-test or matched-pairs test, and differences in the survival rates were analyzed with the log-rank test. Results： TIP30 protein expression was significantly reduced in BUC tissue （t = -6.91, P 〈 0.05） compared with normal tissue samples, and in invasive bladder cancer （t = 10.89, P 〈 0.05） compared with superficial bladder cancer. TIP30 protein expression differed significantly among different differentiated groups classified either according to the World Health Organization （2004, F = 17.48, P 〈 0.01） or World Health Organization （1973, F = 10.68, P 〈 0.01）. TIP30 protein expression was significantly reduced in high-grade papillary urothelial carcinoma compared with papillary urothelial neoplasm of low malignant potential （P 〈 0.05） and low-grade papillary urothelial carcinoma （P 〈 0.05）. Meanwhile, TIP30 protein expression was significantly reduced in Grade 111 BUC, compared with Grade I （P 〈 0.05） and Grade 11 （P 〈 0.05）. Patients with low T1P30 expression showed a higher incidence of disease progression than those with high TIP30 expression （t - 2.63, P 〈 0.05）. Kaplan-Meier survival analysis showed a strong positive relationship between TIP30 expression and overall survival （OS） （x^2 = 17.29,展开更多
文摘目的:基于真实世界分析健脾益胃方对胃癌根治术后化疗不良反应及生存期的影响。方法:收集胃癌根治术后行SOX方案辅助化疗的患者,按是否长期接受健脾益胃方治疗分为联合治疗组和单纯化疗组,记录患者化疗不良反应发生情况,Kaplan-Meier法绘制生存曲线,Log-rank法检验两组生存情况差异。结果:共96例患者纳入研究,联合治疗组45例,单纯化疗组51例,3~4度中性粒细胞减低、血小板减低、恶心呕吐、周围神经毒性发生率单纯化疗组显著高于联合治疗组(P=0.013,P=0.008,P=0.025,P=0.045)。联合治疗组与单纯化疗组中位无病生存期分别为33.4 vs 26.1个月,中位总生存期分别为57.7 vs 48.5个月,差异有统计学意义(P=0.011,P=0.002)。结论:健脾益胃方联合SOX方案能减轻化疗不良反应,降低复发率,延长生存期。
文摘目的评价健脾理气抑瘤方联合细胞因子介导的杀伤细胞（cytokine-induced killer,CIK）治疗晚期肝细胞癌（hepatocellular carcinoma,HCC）的临床疗效。方法自2011年1月—2014年1月共纳入60例晚期HCC患者,根据是否愿意服用健脾理气抑瘤方,分为治疗组和对照组,每组30例。两组均给予CIK细胞治疗：CIK细胞1~3×10~9个/次,第1~3天进行静脉滴注,每天1次;同时治疗组予健脾理气抑瘤方汤剂,对照组予辨证中药汤剂,两组均接受2周期以上的治疗。观察两组患者的疾病控制率（disease control rate,DCR）、疾病进展时间（time to progress,TTP）、总生存期（overall su rvival,OS）、体能状态评分（performance status scale,PS）、Child-Pugh评分及不良反应,并作亚组分析。结果截至2014年5月31日,两组所有患者均达到临床终点。治疗组TTP为3.5个月（95%CI 3.30~4.10）,优于对照组2.5个月（95%CI 2.32~2.68）,差异有统计学意义（P〈0.05）;治疗组和对照组DCR分别为36.7%和30.0%,OS为5.2个月（95%CI 4.53~5.87）和4.6个月（95%CI 4.06~5.14）,差异均无统计学意义（P〉0.05）。治疗组治疗后PS[（1.60±0.10）分]低于治疗前[（1.80±0.09）分],差异有统计学意义（P〈0.05）。在PS 0~1、2分和Child-Pugh评分为A级时,治疗组TTP均长于对照组（P〈0.05）。治疗期间两组患者未见明显不良反应。结论健脾理气抑瘤方联合CIK细胞较辨证中药治疗组可延长患者TTP及改善体力状态评分,且在体力状态评分0~2分或Child-Pugh评分为A级的情况下,可能是晚期HCC患者的更优治疗方案。
文摘Background： Tat-interacting protein 30 （TIP30） has been reported to be a tumor suppressor, with reduced or absent expression in various tumors. However, its role in bladder urothelial cancer （BUC） has not been investigated. Therefore, herein, we investigated the expression of T1P30 protein in BUC and normal bladder mucosa and the clinical significance of TIP30 expression in the prognosis of BUC. Methods： We reviewed data from 79 cases of BUC and 15 adjacent tissue samples from 79 patients treated at our institution between 2004 and 2007. TIP30 expression was examined by immunohistochemistry. The relationship between TIP30 expression and tumor stage, histological grade, and survival was analyzed. Differences between groups were evaluated using the t-test or matched-pairs test, and differences in the survival rates were analyzed with the log-rank test. Results： TIP30 protein expression was significantly reduced in BUC tissue （t = -6.91, P 〈 0.05） compared with normal tissue samples, and in invasive bladder cancer （t = 10.89, P 〈 0.05） compared with superficial bladder cancer. TIP30 protein expression differed significantly among different differentiated groups classified either according to the World Health Organization （2004, F = 17.48, P 〈 0.01） or World Health Organization （1973, F = 10.68, P 〈 0.01）. TIP30 protein expression was significantly reduced in high-grade papillary urothelial carcinoma compared with papillary urothelial neoplasm of low malignant potential （P 〈 0.05） and low-grade papillary urothelial carcinoma （P 〈 0.05）. Meanwhile, TIP30 protein expression was significantly reduced in Grade 111 BUC, compared with Grade I （P 〈 0.05） and Grade 11 （P 〈 0.05）. Patients with low T1P30 expression showed a higher incidence of disease progression than those with high TIP30 expression （t - 2.63, P 〈 0.05）. Kaplan-Meier survival analysis showed a strong positive relationship between TIP30 expression and overall survival （OS） （x^2 = 17.29,
